DC
KRSA

Davenport & Co’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Davenport & Co’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-93
Closed -$7K – 999
2022
Q2 		$7K Hold
93
– – ﹤0.01% 986
2022
Q1 		$14K Buy
93
+2
+2% +$48 ﹤0.01% 1057
2021
Q4 		$22K Buy
+91
New +$4.3K ﹤0.01% 1072
2021
Q2 		– Sell
-604
Closed -$236K – 950
2021
Q1 		$236K Buy
604
+475
+368% +$35.7K ﹤0.01% 718
2020
Q4 		$55K Buy
+129
New +$8.79K ﹤0.01% 774

Other funds holding KRSA

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TFS
TrustCore Financial Services Brentwood, Tennessee $1.14B AUM 13.32% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Davenport & Co's KRSA Position: Q3 2022 in Review

Davenport & Co sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q3 2022, closing a stake of 93 shares — an estimated $7K sold.

Davenport & Co first reported a position in KRSA in Q4 2020 and held it in 5 quarters. The position peaked at $236K in Q1 2021. 34 funds tracked by Wall St. Rank hold KRSA as of Q3 2022.

  • Davenport & Co reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Davenport & Co sold 93 Korsana Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $7K.
  • Davenport & Co first reported a position in Korsana Biosciences, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • Davenport & Co's Korsana Biosciences, Inc. Common Stock position peaked at $236K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q3 2022.

Based on Davenport & Co's 13F filing for Q3 2022, filed 11 Oct 2022.